Angiographic and Clinical Outcomes of the Thin-Strut MAGNITUDE Bioresorbable Scaffold in Patients with Below-the-Knee Arterial Disease: Early Results from the RESOLV I Trial

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Grant Support/Research Contract - AstraZenca; Cook Medical; Bard Medical; Medtronic
• Consultant Fee/Honoraria/Speaker's Bureau - Medtronic; CSI; Bard Medical; Janssen; Cook Medical; Philips